Updated efficacy and safety data from a phase II, single-arm, open-label study of durvalumab plus gemcitabine, cisplatin, and nab-paclitaxel (DurGAP) in resectable biliary tract cancer

Updated efficacy and safety data from a phase II, single-arm, open-label study of durvalumab plus gemcitabine, cisplatin, and nab-paclitaxel (DurGAP) in resectable biliary tract cancer

Background: Our previous research (2024 ASCO Abstract: e16260) highlighted the efficacy and safety data of DurGAP in resectable biliary tract cancer (BTC). This study aims to provide an updated analysis of the safety and efficacy of neoadjuvant DurGAP for resectable BTC in our latest cohort of 30 pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Huikai Li, Yang Liu, Xihao Zhang
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:The Lancet Regional Health. Western Pacific
Online Access:http://www.sciencedirect.com/science/article/pii/S266660652400347X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items